Streetbeat News

Revenues

DIS

Disney unveiled a bold lineup of new attractions and park expansions at D23, including new lands themed around Disney villains, Cars, and Monsters Inc., as well as new Marvel and Avatar attractions. These expansions reflect Disney's ambitious growth strategy in the experiences industry.

Portfolio Pulse from Akanksha Bakshi

August 12, 2024 | 3:02 pm

NEARUSD

NEAR Protocol's price increased by 3.11% in the past 24 hours to $4.09, marking a 16% rise over the past week. Despite the price increase, trading volume has tumbled 73% over the past week, and the circulating supply has slightly decreased. NEAR Protocol's market cap is currently ranked #23 at $4.51 billion.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:01 pm

HSY

In the past three months, 13 analysts have provided ratings for Hershey (NYSE:HSY), with a mix of bullish, bearish, and neutral perspectives. The average 12-month price target has decreased by 3.07% to $198.23. Recent analyst actions include downgrades and lowered price targets from firms like Goldman Sachs, RBC Capital, and Deutsche Bank. Hershey's financials show a decline in revenue growth but strong profitability and return metrics.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:01 pm

LNG

The article provides a comprehensive analysis of Cheniere Energy (NYSE:LNG) compared to its peers in the Oil, Gas & Consumable Fuels industry. Key financial metrics such as P/E, P/B, P/S, ROE, EBITDA, gross profit, and revenue growth are evaluated. Cheniere Energy shows a low P/E ratio, high P/B ratio, low P/S ratio, high ROE, low EBITDA, low gross profit, and negative revenue growth compared to industry averages.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

OUST

In the last three months, 7 analysts have shared their evaluations of Ouster (NYSE:OUST), showing a range of outlooks from bullish to indifferent. The average 12-month price target has risen by 5.29% to $14.14. Analysts from WestPark Capital and Rosenblatt maintain a 'Buy' rating with a $17.00 price target, while Cantor Fitzgerald maintains a 'Neutral' rating with a $13.00 price target. Ouster has shown significant revenue growth but faces challenges in profitability and return metrics.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

BSX

The article provides an in-depth analysis of Boston Scientific (NYSE:BSX) compared to its competitors in the Health Care Equipment & Supplies industry. Key financial metrics such as P/E, P/B, P/S, ROE, EBITDA, and gross profit are examined to offer insights into the company's market position and growth prospects.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

GLPI

Analysts have provided mixed ratings for Gaming and Leisure Properties (NASDAQ: GLPI) over the past three months, with a recent average 12-month price target of $52.1. The company has shown strong financial health with notable revenue growth, high net margins, and efficient use of equity and assets.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

AAPL

HPE

NTAP

PSTG

SMCI

The article provides a comprehensive analysis of Super Micro Computer (NASDAQ:SMCI) against its competitors in the Technology Hardware, Storage & Peripherals industry. Key financial metrics such as P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth are compared. SMCI shows potential undervaluation with low P/E, P/B, and P/S ratios but has lower profitability metrics. However, its high revenue growth and favorable debt-to-equity ratio indicate strong future performance.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

AME

AMETEK (NYSE:AME) has significantly outperformed the market over the past 20 years, delivering an average annual return of 15.86%. A $100 investment in AME 20 years ago would be worth $1,871.32 today. The article highlights the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 12, 2024 | 3:00 pm

JNJ

Medicare and its beneficiaries are paying significantly more for Johnson & Johnson's (NYSE:JNJ) psoriasis drug Stelara when obtained through pharmacies rather than administered in physician offices. The cost discrepancy is due to differing payment determination methods between Medicare Part B and Part D. Recent changes in coverage have led to higher out-of-pocket costs for enrollees, with Medicare expenditures for Stelara increasing almost tenfold from 2016 to 2023.

Portfolio Pulse from Vandana Singh

August 12, 2024 | 2:54 pm